Orexo Interim Report Q2 2020
Investing in diversification to drive future growth Q2 2020 highlights · Total net revenues of SEK 179.1 m (201.2) · EBITDA of SEK -9.0 m (60.4), positive EBITDA of SEK 26.5 m (60.4) excluding accelerated DTx US launch · Net earnings of SEK -32.5 m (54.6), positive net earnings SEK 3.0 m (54.6) excluding accelerated DTx US launch · US Pharma (ZUBSOLV® US) net revenues of SEK 172.5 m (184.4), EBIT of SEK 88.8 m (83.8) · DTx EBIT of SEK -35.5 m (-) · Cash flow from operating activities of SEK -7.2 m (46.1), a cash balance of SEK 677.2 m (697.0) · Completed the